image text translation
“Cancer patients who received the coronavirus vaccine; survival time doubled”
Research from Cham MD Andersson Cancer Center was published in ‘Nature’ on the 22nd
“The average survival time for lung cancer patients increased from 21 months to 37 months.”
‘”Vaccine improves the effectiveness of cancer treatment”
image text translation
The research team analyzed the medical records of more than 1,000 herd cancer and skin cancer (melanoma) patients to arrive at these conclusions.
There is no gain.
According to the study, patients who received the coronavirus mRNA vaccine within 100 days of starting cancer treatment had a live birth rate.
The duration is noticeably absent. For example, for lung cancer patients, the average survival time is 21 to 37 months.
Also, among patients who are facing melanoma, a skin cancer, those who have not received the vaccine are on average.
Although there is no survival time of 27 months, those who received the vaccine survived on average until the end of data collection.
They survive for so long that the period cannot be calculated.
Cancer patients who received the coronavirus vaccine cannot calculate their survival time until the end of data collection -> They are living longer.
image text translation
Corona vaccine acts as an immune treatment ‘booster’
In particular, patients who do not respond well to existing immunotherapy treatments have significantly shorter survival times.
Immunotherapeutics are also commonly called immune checkpoint drugs. To avoid cancer from being attacked by immune cells
Helps the body’s immune system to attack cancer cells again by lifting the ‘immune brake’
It’s about lung cancer. Although it may be effective in skin cancer, more than half of all patients have an immune response.
Because this does not occur sufficiently, the drug list is limited.
The research team found that patients who did not have a sufficient immune response even after receiving immunotherapy treatment in this way were diagnosed with COVID-19.
If you get the NA vaccine, it is said that the vaccine acts as a booster to wake up the ‘latent immune system’.
Corona vaccine acts as a booster to increase the low immune status of cancer patients.
image text translation
C”The timing of vaccination is key
However, the effect varies depending on the timing of vaccination. Within 100 days of starting treatment, especially 30 days before and after treatment
Patients who have received the Corona mRNA vaccine have the least effect. On the other hand, flu or pneumonia
This kind of survival improvement is not seen in vaccines that use mRNA technology like God.
Vaccines other than the LNP-mRNA vaccine have no effect, and vaccination within 100 days of starting chemotherapy and within 30 days before or after treatment shows the greatest effect.
image text translation
nature
Explore content
About the journal
Publish with us
nature
articles
article
Article
Qpen access
Published: 22 October 2025
SARS-CoV-2 mRNA vaccines sensitizetumoursto
immune checkpoint blockade
Adam_Grippin
Christiano Marconi
Copling NanLi Chen Braun Cole Woody Elliana Young Priti
Gupta Min Wang Annette Wu Seong Dong Jeong; Dhruvkumar Soni Erances Weidert Chao Xie Eden
Goldenberg; Andrew Kim; Chong Zhao
Anna DeVries Paul Castillo Rishabh Lohray Michael K Rooney
Benjamnh Schrank Yifan Wang Yifan Ma D3CODE Team
StevenH Ln’s
Show authors
Nature (2025)
Cite this article
Sage
This content was published in ‘Nature’ on October 22, 2025
Looking at the speculations and data on the principle, the vaccine itself has an immune boosting effect, but ultimately
It is believed that the reactivity of ICI (PD-L1 immune checkpoint inhibitor) has increased and the efficacy of the drug has been maximized.
image text translation
Unrrscc:ab 5t370
NISLLL
Gaha-6
NSCLC;
HPaal
0.51,9593
027_7
I: All
CIIe1
HA
037, 5333
CJ.10 hi rice
CUJtJ mHNA uncishn
COVID mPrA reccinc
GU”MIDriiiygr”1I
E 21 * 10 `
dUPBB
ULLI
8-n
‘–n
arCr-
Monrhg lnm
Hotlrs lreo ICI ge-
Vrhafrom
– :II
energy
MACTIII4
CGIDIIS MA
UVuIillhla
MNli”IIu
WA-V
accri
V7-CT –
GUJJe IVtrbrirni
iIL151+
hrrtll
hirstt
HP vs.
0.6J, g54
J.20 U9 won
Apply 3″7
You1-I74
COVID rIiFNA saccitit
INW4
CIII nINIA Mgurie
WPcNJne
Ci737
1 vBrte
Montns trrm ICil 5cart
VorJs ITT
VBLrsuIe
Yaur
LLNUJ mHFI
CyvU mHFua
VUe
PaA
The target group is skin cancer and lung cancer patients. Red is the group of patients who received the Vexin
Shows a clear difference (data from over 1000 people)
conclusion
The X-rona vaccine has a very positive effect in prolonging survival for cancer patients receiving immune checkpoint inhibitors.
* Just in case, I checked to see if the author was related to Moderna or Pfizer, but could not confirm. And because the patient group is large, there is little room for data manipulation.